Hypertrophic cardiomyopathies requiring more monitoring for less atrial fibrillation-related complications: a clustering analysis based on the French registry on hypertrophic cardiomyopathy (REMY)

[1]  A. Ghofrani,et al.  Tachykardien bei pulmonalarterieller Hypertonie , 2020, Herzschrittmachertherapie + Elektrophysiologie.

[2]  P. Elliott,et al.  Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. , 2019, JAMA cardiology.

[3]  Jeroen J. Bax,et al.  Prevalence and Prognostic Implications of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy. , 2019, The American journal of cardiology.

[4]  T. Murohara,et al.  Prognostic impact of mitral L-wave in patients with hypertrophic cardiomyopathy without risk factors for sudden cardiac death , 2019, Heart and Vessels.

[5]  D. Sánchez-Quintana,et al.  Anatomy, Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[6]  B. Maron,et al.  Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". , 2019, Circulation.

[7]  X. Jouven,et al.  Influence of centre expertise on the diagnosis and management of hypertrophic cardiomyopathy: A study from the French register of hypertrophic cardiomyopathy (REMY). , 2019, International journal of cardiology.

[8]  E. Ashley,et al.  Time based versus strain based myocardial performance indices in hypertrophic cardiomyopathy, the merging role of left atrial strain , 2018, European heart journal cardiovascular Imaging.

[9]  S. Ratcliffe,et al.  Atrial fibrillation symptom clusters and associated clinical characteristics and outcomes: A cross-sectional secondary data analysis , 2018, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[10]  G. Boriani,et al.  Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators , 2018, Circulation. Arrhythmia and electrophysiology.

[11]  S. Ommen,et al.  Predictors of Exercise Capacity in Patients with Hypertrophic Obstructive Cardiomyopathy , 2018, Journal of clinical medicine.

[12]  S. Pecha,et al.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management. , 2018, Journal of atrial fibrillation.

[13]  C. Autore,et al.  Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. , 2017, International journal of cardiology.

[14]  A. Manolis,et al.  Atrial fibrillation and arterial hypertension , 2017, Pharmacological research.

[15]  G. Giannakoulas,et al.  Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortality. , 2017, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[16]  G. Lip,et al.  Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes , 2017, American journal of hypertension.

[17]  R. Omar,et al.  Predictors of atrial fibrillation in hypertrophic cardiomyopathy , 2016, Heart.

[18]  B. Gersh,et al.  Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. , 2016, European heart journal cardiovascular Imaging.

[19]  Faisal Rahman,et al.  Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis , 2016, Nature Reviews Cardiology.

[20]  Erwan Donal,et al.  EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. , 2016, European heart journal cardiovascular Imaging.

[21]  R. Omar,et al.  Prediction of thrombo‐embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk‐CVA) , 2015, European journal of heart failure.

[22]  Sudha Seshadri,et al.  50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study , 2015, The Lancet.

[23]  S. Plein,et al.  Cardiovascular imaging practice in Europe: a report from the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[24]  Gustavo Saposnik,et al.  Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis , 2015, The Lancet Neurology.

[25]  S. Bauersachs,et al.  Serum microRNA profiles in cats with hypertrophic cardiomyopathy , 2015, Molecular and Cellular Biochemistry.

[26]  F. Rutten,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[27]  B. Maron,et al.  Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. , 2014, The American journal of cardiology.

[28]  P. Elliott,et al.  Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review , 2013, Heart.

[29]  Michael A Rosenberg,et al.  Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. , 2012, European heart journal.

[30]  Peter Bühlmann,et al.  MissForest - non-parametric missing value imputation for mixed-type data , 2011, Bioinform..

[31]  T. Kubo,et al.  Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[32]  J. Oh,et al.  The mitral annular middiastolic velocity curve: functional correlates and clinical significance in patients with left ventricular hypertrophy. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[33]  Seok‐Min Kang,et al.  Tissue Doppler-derived indices predict exercise capacity in patients with apical hypertrophic cardiomyopathy. , 2005, Chest.

[34]  B. Maron,et al.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[35]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[36]  Y. Doi,et al.  Hypertrophic cardiomyopathy in the elderly: significance of atrial fibrillation. , 2001, Journal of cardiology.

[37]  B. Maron,et al.  Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration. , 1997, Heart.

[38]  B. Maron,et al.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. , 1995, Journal of the American College of Cardiology.

[39]  M. Burch,et al.  Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.

[40]  B. Maron,et al.  Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation. , 1992, The American journal of cardiology.

[41]  M. Frenneaux,et al.  Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. , 1990, Journal of the American College of Cardiology.

[42]  B. Maron,et al.  Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. , 1989, Journal of the American College of Cardiology.

[43]  Mostafa El Qannari,et al.  ClustVarLV: An R Package for the Clustering of Variables Around Latent Variables , 2015, R J..

[44]  E. D. Wigle,et al.  Expert consensus document American College of Cardiology / European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy , 2003 .